Drug intelligence / Profile preview

MRC375

Development stage: Unknown
Lead developer: Molecular Research Center
Modality: Small Molecules
Administration: Oral

Overview

MRC375 is an investigational oral drug being evaluated for the treatment of moderate to severe rheumatoid arthritis. It is currently in Phase 2 clinical trials, where it is administered as a pill and studied for its ability to reduce joint inflammation and pain. The drug appears to have a novel mechanism involving the MORC family of proteins, which are implicated in chromatin remodeling and epigenetic regulation—pathways not typically targeted by standard rheumatoid arthritis therapies. There are also indications that MRC375 may possess antibacterial properties[6].

Beyond the preview

Go deeper on MRC375.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MRC375.

Explore the full profile